• Evotec unit Just – Evotec Biologics started a first-in-human Phase 1 trial of JST-018, an investigational monoclonal antibody cocktail targeting orthopoxviruses.
• Program was developed under the U.S. Department of War Accelerated Antibodies Program, positioning the asset as a prophylactic countermeasure for warfighters.
• Just – Evotec Biologics handled process development, regulatory submission, cGMP manufacturing at its J.POD Redmond site using continuous bioprocessing.
• Orthopoxvirus contract follows a 2022 plague antibodies award; the two contracts carry combined potential value of up to $123.9 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2395956_en) on September 09, 2026, and is solely responsible for the information contained therein.